RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0044-1779488
5-Fluorouracil-Induced Leukoencephalopathy: Report of Two Cases and Review of Literature
Funding None.
Abstract
5-fluorouracil (5FU) forms an important component of chemotherapy regimens used in various gastrointestinal (GI) adenocarcinomas and head and neck squamous cell carcinomas. Leukoencephalopathy is a rare adverse effect of 5FU, mediated by hyperammonemia and hyperlactatemia. We report cases of two patients with GI adenocarcinomas who developed neurological symptoms while on 5FU infusion. The neuroimaging and biochemical parameters were suggestive of toxic leukoencephalopathy. They were managed with cessation of the drug and short-term antiepileptic therapy. We also discuss the pathophysiology of this adverse effect and its management.
Patient Consent
None declared.
Author Contributions
S.R.N. wrote the manuscript and contributed to the intellectual content of the study. S.H. and A.J. reviewed the manuscript and contributed to the intellectual content of the study. The manuscript has been read and approved by all the authors and it represents honest work.
Publikationsverlauf
Artikel online veröffentlicht:
27. September 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Poon MA, O'Connell MJ, Moertel CG. et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7 (10) 1407-1418
- 2 Moore DH, Fowler Jr WC, Crumpler LS. 5-fluorouracil neurotoxicity. Gynecol Oncol 1990; 36 (01) 152-154
- 3 Yeh KH, Cheng AL. High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 1997; 75 (03) 464-465
- 4 Falvella FS, Caporale M, Cheli S. et al. Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. Int J Mol Sci 2015; 16 (04) 8884-8895
- 5 Jose N, Joel A, Selvakumar RJ. et al. Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-centre case series. J Egypt Natl Canc Inst 2022; 34 (01) 22
- 6 Akitake R, Miyamoto S, Nakamura F. et al. Early detection of 5-FU-induced acute leukoencephalopathy on diffusion-weighted MRI. Jpn J Clin Oncol 2011; 41 (01) 121-124
- 7 Ki SS, Jeong JM, Kim SH. et al. A case of neurotoxicity following 5-fluorouracil-based chemotherapy. Korean J Intern Med (Korean Assoc Intern Med) 2002; 17 (01) 73-77
- 8 Filley CM, Kleinschmidt-DeMasters BK. Toxic leukoencephalopathy. N Engl J Med 2001; 345 (06) 425-432
- 9 Lee WW, Kim JS, Son KR, Kwon HM. Atypical diffusion-restricted lesion in 5-fluorouracil encephalopathy. AJNR Am J Neuroradiol 2012; 33 (07) E102-E103
- 10 Lucato LT, McKinney AM, Short J, Teksam M, Truwit CL. Reversible findings of restricted diffusion in 5-fluorouracil neurotoxicity. Australas Radiol 2006; 50 (04) 364-368
- 11 Yoshimura K, Tokunaga S, Daga H, Inoue M. Capecitabine-induced leukoencephalopathy. Intern Med 2019; 58 (04) 621-622
- 12 Videnovic A, Semenov I, Chua-Adajar R. et al. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. Neurology 2005; 65 (11) 1792-1794 , discussion 1685
- 13 Ohara S, Hayashi R, Hata S, Itoh N, Hanyu N, Yamamoto K. Leukoencephalopathy induced by chemotherapy with tegafur, a 5-fluorouracil derivative. Acta Neuropathol 1998; 96 (05) 527-531
- 14 Hayashi R, Hanyu N, Kitahara A. Leukoencephalopathy induced by tegafur: serial studies of somatosensory evoked potentials and cerebrospinal fluid. Intern Med 1992; 31 (06) 828-831
- 15 Janjua TK, Hassan M, Afridi HK, Zahid NA. Oxaliplatin-induced posterior reversible encephalopathy syndrome (PRES). BMJ Case Rep 2017; 2017: bcr2017221571
- 16 Ogata T, Satake H, Ogata M, Hatachi Y, Yasui H. Oxaliplatin-induced hyperammonemic encephalopathy in a patient with metastatic pancreatic cancer: a case report. Case Rep Oncol 2017; 10 (03) 885-889
- 17 Rahal AK, Truong PV, Kallail KJ. Oxaliplatin-induced tonic-clonic seizures. Case Rep Oncol Med 2015; 2015: 879217
- 18 Carson KR, Newsome SD, Kim EJ. et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 2014; 120 (16) 2464-2471
- 19 Sehn LH, Herrera AF, Flowers CR. et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020; 38 (02) 155-165
- 20 Martín G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 2007; 25 (23) 3559
- 21 Levy A, Benmoussa L, Ammari S, Albiges L, Escudier B. Reversible posterior leukoencephalopathy syndrome induced by axitinib. Clin Genitourin Cancer 2014; 12 (01) e33-e34
- 22 Cabanillas ME, Habra MA. Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev 2016; 42: 47-55
- 23 Chelis L, Souftas V, Amarantidis K. et al. Reversible posterior leukoencephalopathy syndrome induced by pazopanib. BMC Cancer 2012; 12: 489
- 24 Roos-Weil D, Weiss N, Guihot A. et al. Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard?. J Neurol 2021; 268 (07) 2458-2465